

NCCN Guidelines for Genetics/Familial High-Risk Assessment: Breast and Ovarian V.1.2016 – Web teleconference on 11/10/15

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>GENE-1 External request Submission request from Myriad Genetic Laboratories to replace the 2nd bullet on GENE-1 with “As many patients have phenotypes that overlap more than one gene/syndrome, clinicians should give strong consideration to multi-gene panel testing when a patient is being assessed for genetic risk. Challenges to testing for only one gene at a time include syndrome overlap, complex or unknown family histories, and inefficiencies in sequential testing.”</p>	<p>For the multi-gene testing page, the panel consensus was to not replace the 2nd bullet which currently reads, “Patients who have a personal or family history suggestive of a single inherited cancer syndrome are most appropriately managed by genetic testing for that specific syndrome. When more than one gene can explain an inherited cancer syndrome, then multi-gene testing may be more efficient and/or cost-effective.” with the suggested text.</p> <p>See Submission for references.</p>	0	20	0	6
<p>ADDIT-2 Internal request Institutional review comment to move the genes “RAD51C, RAD51D and BRIP1” to the row for “Intervention warranted based on gene and/or risk level” for consideration of risk-reducing salpingo-oophorectomy (RRSO).</p> <p>External request Submission request from Myriad Genetic Laboratories to move RAD51C, RAD51D and BRIP1 to the “Intervention Warranted based on gene and/or risk level” section of the table for RRSO.</p>	<p>Based on the references and panel discussion, the consensus was to move RAD51C, RAD51D and BRIP1 to the “Intervention Warranted based on gene and/or risk level” section of the table for RRSO.</p> <p>See Submission for references.</p>	20	0	0	6
<p>External request Submission request from</p>	<p>Based on the panel discussion, the consensus was to not include a table addressing management for patients negative for genetic testing but with a</p>	0	20	0	6

NCCN Guidelines for Genetics/Familial High-Risk Assessment: Breast and Ovarian V.1.2016 – Web teleconference on 11/10/15

Myriad Genetic Laboratories to add a “Familial Risk Management” table addressing management for patients negative for genetic testing but with a family history of cancer. See Submissions for details.	family history of cancer See Submission for references.				
---	--	--	--	--	--